DBP's first patent family for SI-053, which protects a formulation, has been granted in Europe, USA, Eurasia and India and is also expected to be granted in other important markets during 2021-2022. With today's patent application, DBP has started work with the next patent family to further broaden the patent protection for the product.

"With very promising preclinical results, we are very optimistic about SI-053's therapeutic market potential - comments Igor Lokot, CEO of DBP. - We will ensure market exclusivity for our product as a prerequisite for their successful global commercialization."

More about Temodex/SI-053: Temodex, which is a locally acting formulation of temozolomide developed by RI PCP in Minsk, Belarus, is registered for marketing as the first-line treatment of glioblastoma within Belarus since 2014. Temodex was acquired by DBP in autumn 2015 and is now being prepared under the name SI-053 to pass through all the tests and trials required for registration within the EU and globally. Video presentation: https://youtu.be/iweOQPq316o

This disclosure contains information that DBP is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 25-03-2021 20:35 CET.